[
  {
    "ts": null,
    "headline": "ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines",
    "summary": "AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.",
    "url": "https://finnhub.io/api/news?id=bb9f004af89fcbe3f28aaef14c41a6d7495c564644903b82c6d73bfbb183f805",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752683700,
      "headline": "ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines",
      "id": 135993603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.",
      "url": "https://finnhub.io/api/news?id=bb9f004af89fcbe3f28aaef14c41a6d7495c564644903b82c6d73bfbb183f805"
    }
  },
  {
    "ts": null,
    "headline": "Should You Continue to Hold Veracyte Stock in Your Portfolio Now?",
    "summary": "VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.",
    "url": "https://finnhub.io/api/news?id=e88f85408442ec3b5a11524e99146c2b83960a20ad191c1c3e6232392dfaa407",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752669480,
      "headline": "Should You Continue to Hold Veracyte Stock in Your Portfolio Now?",
      "id": 135994177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.",
      "url": "https://finnhub.io/api/news?id=e88f85408442ec3b5a11524e99146c2b83960a20ad191c1c3e6232392dfaa407"
    }
  }
]